See more : Athena Consumer Acquisition Corp. (ACAQ) Income Statement Analysis – Financial Results
Complete financial analysis of Cardio Diagnostics Holdings, Inc. (CDIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardio Diagnostics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Brookfield BRP Holdings (Canada (BEPI) Income Statement Analysis – Financial Results
- National Petroleum Co., Ltd. (9937.TW) Income Statement Analysis – Financial Results
- SAM HOLDINGS (9G2.SI) Income Statement Analysis – Financial Results
- Valterra Resource Corporation (VRSCF) Income Statement Analysis – Financial Results
- CFOAM Limited (CFO.AX) Income Statement Analysis – Financial Results
Cardio Diagnostics Holdings, Inc. (CDIO)
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 17.07K | 950.00 | 901.00 | 0.00 |
| Cost of Revenue | 0.00 | 16.00K | 0.00 | 0.00 |
| Gross Profit | 17.07K | -15.05K | 901.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -1,584.21% | 100.00% | 0.00% |
| Research & Development | 145.18K | 40.45K | 31.47K | 1.50K |
| General & Administrative | 6.94M | 4.40M | 470.56K | 591.52K |
| Selling & Marketing | 158.51K | 92.70K | 103.32K | 5.48K |
| SG&A | 7.10M | 4.49M | 573.88K | 597.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 4.00K |
| Operating Expenses | 7.26M | 4.55M | 621.35K | 609.16K |
| Cost & Expenses | 7.26M | 4.55M | 621.35K | 609.16K |
| Interest Income | 1.07K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.74M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 111.62K | 16.00K | 16.00K | 10.67K |
| EBITDA | -1.53M | -4.64M | -604.45K | -598.50K |
| EBITDA Ratio | -8,966.90% | -465,254.42% | -67,086.35% | 0.00% |
| Operating Income | -7.24M | -4.55M | -620.45K | -609.16K |
| Operating Income Ratio | -42,440.43% | -478,784.32% | -68,862.15% | 0.00% |
| Total Other Income/Expenses | -1.13M | -112.53K | 0.00 | 4.00K |
| Income Before Tax | -8.38M | -4.66M | -620.45K | -605.16K |
| Income Before Tax Ratio | -49,087.81% | -490,630.00% | -68,862.15% | 0.00% |
| Income Tax Expense | 0.00 | 112.53K | 2.00 | 0.00 |
| Net Income | -8.38M | -4.66M | -620.45K | -605.16K |
| Net Income Ratio | -49,087.81% | -490,630.00% | -68,862.15% | 0.00% |
| EPS | -0.66 | -1.51 | -0.53 | -0.06 |
| EPS Diluted | -0.66 | -1.51 | -0.53 | -0.06 |
| Weighted Avg Shares Out | 12.69M | 3.09M | 1.16M | 9.51M |
| Weighted Avg Shares Out (Dil) | 12.69M | 3.09M | 1.16M | 9.51M |
Healing Sanctuary Clinic Partners With Cardio Diagnostics Holdings Inc to Offer the Epi+Gen CHD Test in their Medical Practice in Idaho
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a leading precision cardiovascular diagnostics company, and Healing Sanctuary Clinic, a leading medical practice serving health-forward consumers in Idaho, today announced the availability of Cardio Diagnostics’ Epi+Gen CHD test in Idaho. As a...
Cardio Diagnostics Holdings Inc to Attend 41st Annual JP Morgan Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a precision cardiovascular diagnostics company, announced today that it will attend the JP Morgan Healthcare Conference, January 9-12, 2023. The JP Morgan Healthcare Conference, which will be held in San Francisco, is an...
Houston Concierge Medicine Partners With Cardio Diagnostics to Offer the Epi+Gen CHD Test in Their Executive Health Program
HOUSTON--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a leading precision cardiovascular diagnostics company, and Houston Concierge Medicine, a leading medical practice serving executives and health-forward consumers in Houston, today announced the use of Cardio Diagnostics’ Epi+Gen CHD test. This test,...
Cardio Diagnostics to Present at the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc (Nasdaq: CDIO) today announced it would be presenting at the Benchmark Company’s 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1st, 2022, at the New York Athletic Club in New York City....
Cardio Diagnostics to Present at the Benchmark Company's Upcoming Discovery One-on-One Investor Conference
CHICAGO--( BUSINESS WIRE )--Cardio D iagnostics Holdings Inc (Nasdaq: CDIO) today announced it would be presenting at the Benchmark Company's 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1st, 2022, at the New York Athletic Club in...
Cardio Diagnostics Named to Fast Company’s Second Annual List of the Next Big Things in Tech
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics (Nasdaq: CDIO), a precision cardiovascular disease company, today announced that it has been named to Fast Company’s second annual Next Big Things in Tech list, honoring technology breakthroughs that promise to shape the future of industries—from agriculture...
Cardio Diagnostics Holdings Inc Sponsors the Illinois Association of Medicaid Health Plan’s Annual Conference
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) today announced that it is sponsoring the Illinois Association of Medicaid Health Plans’ (IAMHP) Annual Conference entitled “Bringing Equity into Focus.” The conference is taking place this week, November 14-16, 2022, at the...
Cardio Diagnostics Holdings Inc CEO Meesha Dogan, Accepted into Forbes Technology Council
CHICAGO--(BUSINESS WIRE)--Meesha Dogan, PhD, the CEO of Cardio Diagnostics (Nasdaq: CDIO), a precision cardiovascular disease company, has been accepted into Forbes Technology Council, an invitation-only community for world-class CIOs, CTOs, and technology executives. Cardio Diagnostics is a biotechnology company that...
Cardio Diagnostics Holdings Inc Sponsors Becker’s Hospital Review 11th Annual Meeting - The CEO + CFO Roundtable
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) today announced that it is sponsoring Becker’s Hospital Review 11th Annual Meeting, “The CEO + CFO Roundtable.” The conference is taking place this week, November 7-10, 2022, at the Hyatt Regency Hotel in...
Cardio Diagnostics Holdings, Inc. to List on Nasdaq Following Successful Business Combination with Mana Capital Acquisition Corp.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. ("Cardio" or the “Company”), a pioneering precision cardiovascular medicine company at the intersection of epigenetics and artificial intelligence whose products enable improved prevention, early detection and treatment of cardiovascular disease, today announced the completion of...
Source: https://incomestatements.info
Category: Stock Reports